Zhitong Finance App News, Qianjin Pharmaceutical (600479.SH) issued an announcement. Recently, Hunan Qianjin Xiangjiang Pharmaceutical Co., Ltd., a subsidiary of the company, received the “Drug Registration Certificate” for baclofen tablets approved and issued by the State Drug Administration. Baclofen tablets are suitable for severe but reversible muscle spasms caused by multiple sclerosis, and may have a certain curative effect on spasms caused by infectious, degenerative, traumatic, tumors, or spinal cord diseases of unknown cause. According to Moentropy Pharmaceutical data, the total sales of baclofen tablets in the domestic medical market and retail market in 2025 was 247 million yuan.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.